The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity

被引:10
|
作者
Kokona, Despina [1 ,7 ,8 ]
Spyridakos, Dimitris [1 ]
Tzatzarakis, Manolis [2 ]
Papadogkonaki, Sofia [1 ]
Filidou, Eirini [3 ]
Arvanitidis, Konstantinos, I [3 ]
Kolios, George [3 ]
Lamani, Manjunath [4 ,5 ,6 ]
Makriyannis, Alexandros [4 ,5 ,6 ]
Malamas, Michael S. [4 ,5 ,6 ]
Thermos, Kyriaki [1 ]
机构
[1] Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71003, Crete, Greece
[2] Univ Crete, Sch Med, Dept Toxicol, Iraklion 71003, Crete, Greece
[3] Democritus Univ Thrace, Sch Med, Lab Pharmacol, Alexandroupolis 68100, Greece
[4] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA
[5] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA
[6] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA
[7] Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland
[8] Univ Bern, Bern Univ Hosp, Inselspital, Dept BioMed Res, CH-3010 Bern, Switzerland
关键词
2-Arachidonoylglycerol; ABHD6; MAGL; CB1/CB2 cannabinoid receptors; PI3K/Akt; Retina; Neuroprotection; Neuroinflammation; Microglia;
D O I
10.1016/j.neuropharm.2021.108450
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The endocannabinoid system has been shown to be a putative therapeutic target for retinal disease. Here, we aimed to investigate the ability of the endocannabinoid 2-arachidonoylglycerol (2-AG) and novel inhibitors of its metabolic enzymes, alpha/beta-hydrolase domain-containing 6 (ABHD6) and monoacylglycerol lipase (MAGL), a) to protect the retina against excitotoxicity and b) the mechanisms involved in the neuroprotection. Sprague-Dawley rats, wild type and Akt2(-/-) C57BL/6 mice were intravitreally administered with phosphate-buffered saline or (RS)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid hydrobromide (AMPA). 2-AG was intravitreally co-administered with AMPA in the absence and presence of AM251 or AM630 (cannabinoid 1 and 2 receptor antagonists, respectively) or Wortmannin [Phosphoinositide 3-Kinase (PI3K)/Akt inhibitor]. Inhibitors of ABHD6 and dual ABHD6/MAGL (AM12100 and AM11920, respectively) were co-administered with AMPA intravitreally in rats. Immunohistochemistry was performed using antibodies raised against retinal neuronal markers (bNOS), microglia (Iba1) and macroglia (GFAP). TUNEL assay and real-time PCR were also employed. The CB2 receptor was expressed in rat retina (approx. 62% of CB1 expression). 2-AG attenuated the AMPA-induced increase in TUNEL+ cells. 2-AG activation of both CB1 and CB2 receptors and the PI3K/Akt downstream signaling pathway, as substantiated by the use of Akt2(-/-) mice, afforded neuroprotection against AMPA excitotoxicity. AM12100 and AM11920 attenuated the AMPA-induced glia activation and produced a dose-dependent partial neuroprotection, with the dual inhibitor AM11920 being more efficacious. These results show that 2-AG has the pharmacological profile of a putative therapeutic for retinal diseases characterized by neurodegeneration and neuroinflammation, when administered exogenously or by the inhibition of its metabolic enzymes.
引用
收藏
页数:15
相关论文
共 1 条
  • [1] The β2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity
    Gleeson, Lorna C.
    Ryan, Katie J.
    Griffin, Eadaoin W.
    Connor, Thomas J.
    Harkin, Andrew
    BRAIN BEHAVIOR AND IMMUNITY, 2010, 24 (08) : 1354 - 1361